You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 9, 2025

Details for Patent: 12,115,179


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 12,115,179
Title:Pharmaceutical composition, methods for treating and uses thereof
Abstract:The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Inventor(s):Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian BROEDL, Rolf GREMPLER
Assignee:Boehringer Ingelheim International GmbH
Application Number:US18/320,462
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 12,115,179: A Comprehensive Guide

Introduction

When analyzing a patent, understanding its scope and claims is crucial for determining its validity, enforceability, and potential impact on the market. This article will delve into the specifics of United States Patent 12,115,179, using relevant principles and data to provide a detailed analysis.

Understanding Patent Claims

Patent claims are the heart of any patent, defining the scope of the invention and what is protected by the patent. These claims must be clear, concise, and exact to meet statutory requirements[1].

Types of Claims

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit an independent claim.
  • Method Claims: These describe a process or method.
  • Apparatus Claims: These describe a physical device or system.

The Importance of Claim Clarity

Clear and precise claims are essential for ensuring that a patent is valid and enforceable. The USPTO has emphasized the need for clarity through its Enhanced Patent Quality Initiative, which includes measures to improve the clarity of patent applications[1].

Challenges in Claim Clarity

  • Broadly Worded Applications: Nearly 90% of patent examiners encounter broadly worded patent applications, which can make thorough examinations difficult[1].
  • Use of Additional Tools: Tools like glossaries of key terms, check boxes for functional claim language, and claim charts can enhance clarity but are not currently required by the USPTO[1].

Analyzing the Scope of Patent 12,115,179

To analyze the scope of Patent 12,115,179, we need to examine its claims in detail.

Claim Structure

  • Independent Claims: Identify the independent claims that define the core of the invention.
  • Dependent Claims: Analyze how dependent claims further limit the independent claims.
  • Claim Language: Evaluate the clarity and specificity of the claim language.

Example from Allergan USA, Inc. v. MSN Laboratories Private Ltd.

In the case of Allergan USA, Inc. v. MSN Laboratories Private Ltd., the court analyzed the claims of several patents related to eluxadoline, a compound used in treating pain and gastrointestinal disorders. The court's decision highlights the importance of claim distinctness and the written description requirement under 35 U.S.C. § 112[2].

Patent Landscape and Related Patents

Understanding the patent landscape involves identifying related patents and how they interact with the patent in question.

Patent Family

  • Priority Dates: Determine the priority dates of the patent and its related family members.
  • Continuation and Divisional Patents: Identify any continuation or divisional patents that may share a common priority date.

Expiration Dates and Patent Term Adjustments

  • Patent Term: Calculate the patent term, including any adjustments for delays in prosecution.
  • Terminal Disclaimers: Check for terminal disclaimers that may affect the patent term of related patents[2].

Legal and Policy Considerations

The validity and enforceability of a patent are also influenced by legal and policy considerations.

Obviousness-Type Double Patenting

This doctrine prohibits the issuance of multiple patents for the same invention. The court's decision in Allergan USA, Inc. v. MSN Laboratories Private Ltd. clarifies that a first-filed, first-issued claim cannot be invalidated by a later-filed, later-issued claim with a common priority date[2].

Written Description Requirement

The written description requirement under 35 U.S.C. § 112 ensures that the patent specification adequately describes the invention. Failure to meet this requirement can result in the claims being deemed invalid[2].

Economic and Practical Implications

The economic and practical implications of a patent are significant and can impact various stakeholders.

Small Claims Patent Court

The concept of a small claims patent court, studied by the Administrative Conference of the United States (ACUS), aims to provide a more accessible and cost-effective forum for resolving patent disputes. This could have significant implications for patent holders and challengers alike[5].

Patent Scope and Claims Dataset

The USPTO's Patent Claims Research Dataset provides detailed information on claims from U.S. patents and applications, which can be used to analyze trends and metrics related to patent scope and claims. This dataset can help in understanding the broader patent landscape and how Patent 12,115,179 fits within it[3].

Key Takeaways

  • Clear Claims: Clear and precise claims are crucial for patent validity and enforceability.
  • Patent Landscape: Understanding related patents and the overall patent landscape is essential for analyzing the scope of a patent.
  • Legal Considerations: Obviousness-type double patenting and the written description requirement are critical legal considerations.
  • Economic Implications: The economic and practical implications of a patent, including the potential for small claims patent courts, can significantly impact stakeholders.

FAQs

What is the importance of claim clarity in patent applications?

Claim clarity is essential for ensuring that a patent is valid and enforceable. Clear claims help in avoiding ambiguities and make it easier for examiners to conduct thorough examinations[1].

How does the USPTO measure patent quality?

The USPTO measures patent quality through various correctness measures and quantifiable compliance targets, which include statutory compliance rates for different sections of the patent code[1].

What is obviousness-type double patenting?

Obviousness-type double patenting is a doctrine that prohibits the issuance of multiple patents for the same invention. It ensures that an inventor cannot obtain multiple patents for essentially the same invention[2].

Why is the written description requirement important?

The written description requirement under 35 U.S.C. § 112 ensures that the patent specification adequately describes the invention, which is crucial for the validity of the patent claims[2].

What is the purpose of the Patent Claims Research Dataset?

The Patent Claims Research Dataset provides detailed information on claims from U.S. patents and applications, helping in the analysis of trends and metrics related to patent scope and claims[3].

Sources

  1. GAO Report: Intellectual Property: Patent Office Should Define Quality, Reassess Incentives, and Improve Application Review Process. GAO-16-490, June 30, 2016.
  2. Federal Circuit Court Decision: Allergan USA, Inc. v. MSN Laboratories Private Ltd. Case: 24-1061, Document: 37, Filed: 08/13/2024.
  3. USPTO Dataset: Patent Claims Research Dataset. USPTO, August 28, 2017.
  4. ACUS Report: U.S. Patent Small Claims Court. Administrative Conference of the United States, 2022.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 12,115,179

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim SYNJARDY XR empagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208658-001 Dec 9, 2016 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN ⤷  Subscribe
Boehringer Ingelheim SYNJARDY XR empagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208658-002 Dec 9, 2016 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN ⤷  Subscribe
Boehringer Ingelheim SYNJARDY XR empagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208658-003 Dec 9, 2016 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.